STAT July 30, 2024
Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for up to three years experienced less cognitive decline than what’s expected of untreated patients based on historical data, according to new study results reported Tuesday. The manufacturers said the data support long-term, continuous use of the drug.
The three-year benefit seen in patients provided Leqembi remains modest — a 31% slowing of cognitive decline, slightly...
Today's Sponsors
Today's Sponsor